Durvalumab/Pembrolizumab
Fields of Study & Subjects
Cancer Immunotherapy and Biomarkers
Pharmacovigilance and Adverse Drug Reactions
Immunotherapy and Immune Responses
Publication details
- Journal / source
- Reactions Weekly
- Volume
- 2093
- Issue
- 1
- Pages
- 49–49
- Publication date
- 16 January 2026
- Language
- EN